#ESMO26 🧬 B7-H3靶向ADC能否在mCRPC中挑战多西他赛？
BNT324-03，III期TiP研究评估elfetabart drozuntecan (Elfe-D)，一种携带拓扑异构酶I抑制剂载药的B7-H3定向ADC。
📌早期I/II期数据提供依据：
• PSA50：42.9%
• 确认ORR：35.8%
• 中位rPFS：11.3个月
• 在既往¹⁷⁷Lu-PSMA治疗后也观察到活性
📌III期设计：
• N≈736，1:1随机
• Elfe-D 6 mg/kg Q3W 对比 多西他赛 75 mg/m² Q3W
• 既往未接受紫杉烷治疗的mCRPC，经1–2线ARPI后
• 允许既往¹⁷⁷Lu-PSMA及用于mHSPC的多西他赛
• 双主要终点：rPFS和OS
@UroToday @myESMO
118 浏览 · 2 赞 · 2 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Julian Chavarriaga · x.com